The French government has announced a 2000 budget allocation of 150million euros ($136 million) to accelerate the development principally of medium-sized and smaller biotechnology companies, because of their influence on long-term economic growth and contribution to health care. Philippe Pouletty, president of the sector group France Biotech, said the decision was a genuine success for the industry and, if these measures were expanded in the years ahead, France's biotechnology sector could catch up with competitor countries and achieve a leading position in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze